Search clinical trials for: AZD6765

Total 111 results

AstraZeneca

Completed

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects (JSAD/JMAD)

Healthy

United States
AstraZeneca
National Institute of Mental Health (NIMH)

Completed

This is a Study to Determine the Antidepressant Effects of AZD6765

Treatment Resistant Major Depressive Disorder

United States
AstraZeneca

Completed

Study to Assess the Distribution, Metabolism and Excretion of [14C]AZD6765 After a Single-Dose Intravenous Administration (AZD6765)

Major Depressive Disorder

United Kingdom
AstraZeneca

Withdrawn

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

Healthy

United States
AstraZeneca

Completed

AZD6765 for Treatment Resistant Depression

Depression

United States
AstraZeneca

Completed

AZD6765 Severe Major Depressive Disorder (MDD) IV

Major Depressive Disorder

United States
Joseph Paul Eder
Dana-Farber Cancer Institute; The Cleveland Clinic; Vanderbilt-Ingram Cancer...

Terminated

OLAParib COmbinations (OLAPCO)

Cancer

United States
AstraZeneca

Completed

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Chile, Slovakia
Massachusetts General Hospital
AstraZeneca

Recruiting

AZD6738 for Patients With Progressive MDS or CMML

Leukemia | Myelodysplastic Syndrome

United States
AstraZeneca

Completed

Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours

Non-Small Cell Lung Cancer | Advanced Solid Tumours

United States, United Kingdom
Cancer Research UK
AstraZeneca

Completed

A Phase I Trial of AZD3965 in Patients With Advanced Cancer

Adult Solid Tumor | Burkitt Lymphoma | Diffuse Large B Cell Lymphoma

United Kingdom
AstraZeneca

Recruiting

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics (PK) of Oral AZD6793 in Healthy Subjects and to Assess the Relative Oral Bioavailability Between Two Formulations. The Study Will Also Assess the Food Effect on the PK of AZD6793 Compared to Fasting State

Inflammatory Diseases

United Kingdom
AstraZeneca

Not yet recruiting

A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants

Healthy Participants

United States
AstraZeneca

Active, not recruiting

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

Advanced Solid Tumours

United States, France, Spain
AstraZeneca

Terminated

Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients

Type 2 Diabetes

Sweden
Royal Marsden NHS Foundation Trust
AstraZeneca; Cancer Research UK; RM/ICR Biomedical Research Centre

Active, not recruiting

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours (Patriot)

Solid Tumour Refractory to Conventional Treatment

United Kingdom
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
AstraZeneca
Parexel

Terminated

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD6615 in Healthy Subjects

Dyslipidemia

United States
AstraZeneca

Terminated

Oral AZD8165 After Single Oral Ascending Doses in Healthy Male Subjects

Thrombin Inhibition

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
AstraZeneca

Completed

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

Spain, Poland, Hungary, Ukraine, Germany
AstraZeneca

Completed

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients Without Erosive Esophagitis.

GERD Without Erosive Esophagitis

Sweden, United States, France, Italy, United Kingdom, Germany, Denmark, Finland, Norway, Canada
AstraZeneca

Completed

A Dose-finding Phase IIb Study With AZD0865 and Esomeprazole in GERD Patients With Erosive Esophagitis.

GERD With Erosive Esophagitis

Sweden, United States, France, Italy, United Kingdom, Germany, Denmark, Finland, Norway, Canada
AstraZeneca
Parexel

Not yet recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
NYU Langone Health

Terminated

AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myelofibroses

United States
AstraZeneca
Parexel

Recruiting

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Cardiovascular

United States
AstraZeneca

Recruiting

A Randomized Trial Evaluating a mRNA-VLP Vaccine's Immunogenicity and Safety for COVID-19 (ARTEMIS-C)

COVID-19 | SARS-CoV-2 Infection

United States
AstraZeneca

Active, not recruiting

Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy (HUDSON)

Non-Small Cell Lung Cancer

France, Spain, United States, Canada, Korea, Republic of, Austria, Israel, Germany
Seoul National University Hospital

Recruiting

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
Se-Hoon Lee
AstraZeneca

Completed

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects (SUKSES-N4)

Small Cell Lung Cancer

Korea, Republic of
Samsung Medical Center

Active, not recruiting

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Gastric Adenocarcinoma | Malignant Melanoma

Korea, Republic of
Mette M Berger
Texas A&M University

Completed

Can Beta-Hydroxy-beta-Methylbutyrate Supplementation Counteract Muscle Catabolism in Critically Ill Patients? (HMB-ICU-CH)

Critical Illness | Muscle Weakness

Switzerland
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
AstraZeneca

Terminated

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Previously Treated Non Small Cell Lung Cancer

United States
AstraZeneca

Completed

Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.

Ovarian Cancer | Locally Advanced Solid Tumours | Metastatic Solid Tumours

United States
AstraZeneca
Parexel

Terminated

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

Advanced Solid Tumours

United Kingdom, United States
Samsung Medical Center

Completed

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Small Cell Lung Cancer

Korea, Republic of
University of Nottingham

Completed

Investigating the Effects of Beta-Hydroxy-Beta-Methylbutyrate on Glucose Handling in Older and Younger Men.

Insulin Resistance | Age Problems

United Kingdom
Samsung Medical Center

Terminated

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Small Cell Lung Cancer

Korea, Republic of
AstraZeneca
Parexel

Completed

A Study of Adavosertib as Treatment for Uterine Serous Carcinoma (ADAGIO)

Uterine Serous Carcinoma

United States, Italy, Spain, France, Canada
Dana-Farber Cancer Institute
AstraZeneca

Active, not recruiting

AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Uterine Cancer

United States
AstraZeneca
Quintiles, Inc.

Completed

Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours

Solid Tumours

France, United Kingdom, Netherlands
National Cancer Institute (NCI)

Completed

AZD1775 for Advanced Solid Tumors

Solid Tumors

United States
AstraZeneca

Terminated

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer

United States
St. Joseph's Hospital and Medical Center, Phoenix
Barbara Ann Karmanos Cancer Institute; American Society of Clinical Oncology; Translational Genomics Research Institute and other collaborators

Completed

A Phase 0 Study of AZD1775 in Recurrent GBM Patients

Glioblastoma | GBM

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
AstraZeneca
Parexel

Terminated

Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib (ADME)

Advanced Solid Tumors

United Kingdom
National Cancer Institute (NCI)

Completed

AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm

United States
University of Birmingham
AstraZeneca; Cancer Research UK

Completed

WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer (WISTERIA)

Larynx Cancer | Oral Cavity Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma

United Kingdom
AstraZeneca

Completed

Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours

Advanced Solid Tumours

Japan

Search clinical trials for: AZD6765

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations